Skip to main content

Single-Use Sensations: Single-Use Bioprocessing Market Set to Soar Past USD 52.93 Billion by 2030

The Global Single Use Bioprocessing market size is expected to reach USD 52.93 billion by 2030 and exhibit a CAGR of 20.5% in the forecast period (2023−2030), according to Skyquest’s latest research report. The increasing demand for personalized medicine and targeted therapies, the growing biopharmaceutical industry and drug development activities, and the need for cost-effective and time-efficient manufacturing processes fuel the market’s growth.

Westford USA, June 28, 2023 (GLOBE NEWSWIRE) — According to SkyQuest’s latest global research of the Single Use Bioprocessing market, increased adoption of single-use technologies in small-scale bioprocessing, integration of automation and digitalization in single-use bioprocessing, development of high-performance single-use bioreactors, growing use of single-use systems in continuous bioprocessing, expansion of single-use solutions beyond upstream processing to downstream processing, the emergence of closed and aseptic single-use systems, integration of single-use systems in modular and flexible manufacturing facilities, are the trends that aid in the market’s growth.

Browse in-depth TOC on “Single Use Bioprocessing Market”

  • Pages – 242
  • Tables – 91
  • Figures – 76

Single-use bioprocessing is a method of producing biopharmaceuticals, vaccines, and other medical products using disposable equipment. This method has several advantages over traditional methods, including reduced risk of contamination, increased flexibility, and lower costs.

Prominent Players in Single Use Bioprocessing Market

  • BD
  • Baxter
  • Carlisle
  • Eppendorf
  • GE Healthcare
  • Sartorius
  • Thermo Fisher Scientific
  • 3M
  • Asahi Kasei
  • Bio-Rad
  • Danaher
  • Esterline
  • Medivators
  • Mitsubishi Chemical
  • Parker Hannifin
  • Pall
  • Retractable Technologies
  • Sigma-Aldrich
  • Smiths Medical
  • Sotera Health

Get a sample copy of this report:

https://www.skyquestt.com/sample-request/single-use-bioprocessing-market

Single Use Bioreactors Demand to Grow Substantially in the Forecast Period

Single use bioreactors dominated the global online market due to their flexibility and scalability. They allow for easy setup, faster turnaround times, and reduced cross-contamination risks. Single-use bioreactors can be quickly deployed for different processes and easily scaled up or down based on production requirements. The ability to adapt to changing production needs and streamline operations positions single-use bioreactors as a dominant product type in the market.

Vaccine Production is the Leading Application Segment

In terms of application, vaccine production is the leading segment due to the global vaccination efforts. In addition, vaccines typically require large-scale production to meet global demand. Single-use bioprocessing offers advantages in terms of flexibility, scalability, and rapid deployment. The use of single-use bioreactors, containers, and other disposable systems allows for efficient and streamlined vaccine manufacturing processes, making it a preferred choice for large-scale production needs.

Browse summary of the report and Complete Table of Contents (ToC):

https://www.skyquestt.com/report/single-use-bioprocessing-market

North America is the leading Market Due to the Advancements in Pharmaceutical Industry

Region-wise, North America is one of the largest growing markets with a huge emphasis on technological advancements. The region, particularly the United States, has a well-established and advanced biopharmaceutical industry. The region is home to numerous pharmaceutical companies, research institutions, and academic centers actively engaging in drug development, biomanufacturing, and clinical research. The presence of a robust industry ecosystem provides a strong foundation for the adoption and growth of single-use bioprocessing technologies.

A recent report thoroughly analyzes the major players operating within the Single Use Bioprocessing market. This comprehensive evaluation has considered several crucial factors, such as collaborations, mergers, innovative business policies, and strategies, providing invaluable insights into the key trends and breakthroughs in the market. Additionally, the report has carefully scrutinized the market share of the top segments and presented a detailed geographic analysis. Finally, the report has highlighted the major players in the industry and their ongoing endeavors to develop innovative solutions that cater to the ever-increasing demand for Single Use Bioprocessing.

Speak to Analyst for your custom requirements:

https://www.skyquestt.com/speak-with-analyst/single-use-bioprocessing-market

Key Developments in Single Use Bioprocessing Market

  • In February 2023, Sartorius acquired Xcellerex. Xcellerex is a leading provider of single-use bioprocessing systems. The acquisition will help Sartorius to expand its single-use bioprocessing portfolio and reach new markets.
  • In March 2023, Danaher acquired Pall. Pall is a leading provider of single-use bioprocessing filtration products and services. The acquisition will help Danaher to expand its single-use bioprocessing portfolio and reach new markets.

Key Questions Answered in Single Use Bioprocessing Market Report

  • What specific growth drivers are projected to impact the market during the forecast period?
  • Can you list the top companies in the market and explain how they have achieved their positions of influence?
  • In what ways do regional trends and patterns differ within the global market, and how might these differences shape the market’s future growth?

Related Reports in SkyQuest’s Library:

Global Healthcare Smart Beds Market

Global Healthcare Kiosk Market

Global IoT In Healthcare Market

Global 5G Infrastructure in Healthcare Market

Global Advanced Wound Care Market

About Us:

SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email: sales@skyquestt.com

LinkedIn Facebook Twitter

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.